The medical cannabis company Odi Pharma reported revenue in the second quarter compared with none in the same period a year earlier. The operating result showed a turn to profit."Our operations have become significantly more stable compared with previous periods. Operational stability, improved logistics and stronger commercial execution capability have substantially strengthened our financial position. ODI has also consolidated its role as an important player in the Eastern European market. We have significantly exceeded our previous target of achieving a market share of 10 percent and are now a significant player in the region," comments Chairman of the Board Volker Wiederrich.Revenue amounted to SEK 10.9 million (0.0).The operating result was SEK 1.5 million (-2.3), with an operating margin of 13.8 percent. Result both before and after tax was SEK 1.3 million (-2.6). Earnings per share amounted to SEK 0.07 (-0.16). "The return to profitability confirms the scalability of our partner-led and capital-efficient business model," says Wiederrich.Cash flow from operating activities amounted to SEK 1.5 million (-1.9). Cash and cash equivalents amounted to SEK 4.8 million (5.4).Odi Pharma, SEK millionQ2-2025/2026Q2-2024/2025ChangeNet sales10.90.0Operating result1.5-2.3Operating margin13.8%Result before tax1.3-2.6Net income1.3-2.6Earnings per share, SEK0.07-0.16Cash flow from operating activities1.5-1.9Cash and cash equivalents4.85.4-11.1%